Skip to Content
Authors Downs TM, Szilvasi A, O'Donnell MA
Author Profile(s)
Journal J. Urol. Volume: 158 Issue: 6 Pages: 2311-5
Publish Date 1997 Dec
PubMed ID 9366382

To determine if BCG and interferon alpha-2B are mutually compatible as mixed intravesical agents for clinical bladder cancer therapy.Mutual compatibility was assessed by measuring IFN-alpha’s effect on BCG metabolic activity, growth rate, and clumping tendency and conversely by observing BCG’s effect on IFN-alpha’s anti-viral activity. Optical density at 600 nm. (OD600) was used to estimate the number of colony forming units of BCG in suspension during 3 hours measurements of clumping and 8 days measurements of BCG proliferation. BCG viability was evaluated using a substrate marker, MTT, which correlates with BCG density and metabolic activity. The anti-viral activity of IFN-alpha was determined in a cytopathic protection bioassay using the encephalomyocarditis virus/FS-4 cell system.Continuous shaking of reconstituted BCG for 3 hours at 37C resulted in a marginal (11.3%) drop in OD600 which was minimally altered by inclusion of IFN-alpha at 2 million units (MU)/ml. (12.7% drop). Metabolic activity and growth rate of BCG alone or BCG with IFN-alpha were essentially identical. IFN-alpha’s antiviral activity was not affected by incubation with BCG.The inclusion of IFN-alpha into the usual BCG formulation for intravesical administration has no apparent effect on BCG’s viability or tendency to form clumps in suspension. Similarly, the physical mixing of IFN-alpha with BCG does not impair its biological activity. Thus, both agents are pharmacologically compatible for future clinical studies involving combination intravesical therapy. Copyright © 2018 The Board of Regents of the University of Wisconsin System